IBI302 clinical trials
Also written IBI302.
How each study uses IBI302 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IBI302 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IBI302
- 3
Studies by the year they started
6 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 2 |
Who runs them
Industry 6 · Other 0
Innovent Biologics (Suzhou) Co. Ltd. (4) · Innovent Biologics Technology Limited (Shanghai R&D Center) (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test IBI302, phase 3 first.
- Feb 2027A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMDPhase 3 · Innovent Biologics (Suzhou) Co. Ltd.
- Dec 2026A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME)Phase 2 · Innovent Biologics Technology Limited (Shanghai R&D Center)
Studies
Open first, then newest update. How each study uses IBI302 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMDRecruitingPhase 2Innovent Biologics Technology Limited (Shanghai R&D Center)NCT07275840Written as IBI302 8mg dose
- A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME)Active, not recruitingPhase 2Innovent Biologics Technology Limited (Shanghai R&D Center)NCT06908876Written as IBI302
- A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular DegenerationCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT03814291Written as IBI302
- A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMDActive, not recruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT05972473Written as IBI302
- A Study of IBI302 in Patients With nAMDCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT04820452Written as Low dose IBI302
- Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD PatientsCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT04370379Written as IBI302 (the first dose level)